If you’ve spent any time reading about recovery peptides, you’ve almost certainly come across BPC-157. It’s one of the most discussed peptides in Canada and around the world — and for good reason. The research behind it, while still mostly preclinical, is unusually consistent. Study after study in animal models shows the same thing: faster healing across a surprising range of tissue types.
But there’s a lot of noise mixed in with the signal. Social media hype, vague health claims, and a confusing regulatory picture make it hard to figure out what BPC-157 actually is, what the science supports, and what’s still unknown. This guide is meant to cut through that.
What Is BPC-157?
BPC-157 stands for Body Protection Compound-157. It’s a synthetic peptide made up of 15 amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The peptide was first described in the scientific literature in 1993 by a Croatian research team led by Predrag Sikirić.
The “body protection compound” it’s derived from is a larger protein found naturally in human gastric juice — the fluid your stomach produces to protect its own lining from acid. Researchers isolated this 15-amino-acid fragment because it appeared to carry most of the protective and healing activity of the full protein, but in a much smaller, more stable form.
One of the things that makes BPC-157 unusual among peptides is its chemical stability. Most peptides break down quickly in the stomach and bloodstream. BPC-157 stays intact in human gastric juice for over 24 hours, which is part of why researchers have explored both injectable and oral routes of administration.
How BPC-157 Works in the Body
BPC-157 doesn’t do just one thing. It appears to activate several overlapping repair pathways at the same time, which is probably why its effects show up across so many different tissue types. Here are the key mechanisms that have been identified in research so far:
VEGF receptor activation and angiogenesis. The most well-established mechanism. BPC-157 activates the VEGFR2 pathway, which tells the body to build new blood vessels. More blood vessels at an injury site means more oxygen, more nutrients, and faster removal of waste — all of which speed up healing. A 2025 systematic review in an orthopaedic sports medicine journal confirmed this as a primary mechanism across multiple studies.
Growth hormone receptor upregulation. Research published in the journal Life Sciences found that BPC-157 increases the expression of growth hormone receptors on tendon cells. This doesn’t mean it raises your growth hormone levels — it means the cells at the injury site become more responsive to whatever growth hormone is already circulating. The effect was dose-dependent and became more pronounced over three days of treatment.
FAK-paxillin pathway activation. This pathway controls how cells migrate and attach to surfaces. When tissue is damaged, new cells need to physically move into the wound area and anchor themselves. BPC-157 appears to accelerate this process.
Anti-inflammatory effects. Multiple studies show BPC-157 reduces inflammatory cytokines at injury sites. It doesn’t suppress the immune system broadly — it appears to calm down the specific inflammatory response at the location of damage, which allows healing to proceed without the collateral tissue damage that prolonged inflammation can cause.
Nitric oxide (NO) system modulation. BPC-157 interacts with the nitric oxide system in ways that researchers are still working to fully understand. NO is involved in blood vessel dilation, immune signaling, and nerve function, so this connection may explain some of the peptide’s broader effects.
What Has BPC-157 Been Studied For?
The research on BPC-157 covers a wide range of injury and tissue types. Nearly all of it is in animal models — mostly rats — but the consistency of results across different labs and different injury types is what makes it stand out from many other experimental peptides.
Tendon and ligament injuries
This is probably the most studied application. Multiple rat studies have shown accelerated healing of severed Achilles tendons, including faster recovery of biomechanical strength. The peptide appears to work by increasing collagen formation, promoting fibroblast activity, and improving blood supply to the injury site.
Muscle injuries
Studies in rats with surgically detached muscles showed faster reattachment and functional recovery when treated with BPC-157 compared to controls. The effect was observed whether the peptide was administered locally at the injury or systemically.
Bone healing
Animal studies have shown improved bone healing and pseudoarthrosis (non-union fracture) repair with BPC-157 treatment. The peptide appears to support both the early inflammatory phase and the later remodeling phase of bone repair.
Gut healing
Given that BPC-157 originates from gastric juice, its effects on the GI tract have been studied extensively. Animal models show protective effects against ulcers, inflammatory bowel disease, NSAID-induced gut damage, and fistula repair. A 2025 systematic review presented at the American College of Gastroenterology confirmed its potential across multiple GI conditions in preclinical models.
The one human study worth mentioning
A small retrospective case series looked at 12 patients with chronic knee pain who received a single BPC-157 injection into the knee joint. Seven of the 12 reported pain relief lasting more than six months. It’s a genuinely interesting result, but it’s also important to be honest about its limitations: no control group, no standardized pain scoring, and a very small sample size. It’s a starting point, not proof.
Dosing: What the Research Uses
There are no official dosing guidelines for BPC-157 because it hasn’t been through clinical trials. That said, the existing research literature and community experience provide some reference points:
Animal studies typically use 6 to 50 mcg per kilogram of body weight, administered once or twice daily. In human research settings, doses of 200 to 500 mcg per day are most commonly referenced. The peptide can be injected subcutaneously (under the skin), intramuscularly, or taken orally. Its half-life after injection is short — under 30 minutes — which is why some protocols use twice-daily dosing.
For subcutaneous injection, most researchers inject near the site of injury when possible. For gut-related research, oral administration has shown effectiveness in animal models thanks to BPC-157’s unusual stability in gastric acid.
If you’re new to peptides in Canada and want help with the math, our free Peptide Dosage Calculator handles the reconstitution and syringe unit calculations for you.
Safety: What We Know and What We Don’t
The safety profile of BPC-157 in animal studies is remarkably clean. Across dozens of studies spanning three decades, no significant toxicity has been reported in any organ system. A 2025 pilot study gave two healthy adults intravenous BPC-157 at doses of 10 mg and 20 mg (far above typical research doses) and found no adverse effects on cardiac, liver, kidney, thyroid, or blood sugar markers.
That said, there are legitimate concerns to be aware of:
Because BPC-157 promotes angiogenesis (new blood vessel growth), there’s a theoretical concern about its use in anyone with active or undetected cancer. New blood vessels could, in theory, supply blood to tumors. No study has directly tested this, but the mechanism is plausible enough that researchers have flagged it.
The biggest practical safety risk has nothing to do with the peptide itself — it’s about sourcing. If you buy BPC-157 from a supplier that doesn’t provide third-party certificates of analysis, you have no way of knowing what’s actually in the vial. Contamination, mislabeling, and degradation from poor manufacturing are real risks in the peptide market. This is why where you buy matters as much as what you buy.
Stacking BPC-157 with TB-500
One of the most common research protocols pairs BPC-157 with TB-500 (a synthetic fragment of Thymosin Beta-4). The logic is straightforward: the two peptides work through different but complementary mechanisms. BPC-157 focuses on increasing blood flow and growth factor activity at the injury site, while TB-500 promotes cell migration, new blood vessel formation, and reduces inflammation systemically.
Together, they cover more of the healing process than either one alone. This combination has become one of the most popular recovery stacks among peptide researchers in Canada and elsewhere.
Regulatory Status
BPC-157’s legal and regulatory status is complicated and still evolving:
In Canada, BPC-157 is sold legally for research purposes. It is not approved by Health Canada for human therapeutic use. In the United States, the FDA classified it as a Category 2 bulk drug substance in 2023, meaning commercial pharmacies cannot compound it, but it remains legal to possess and purchase as a research chemical. The World Anti-Doping Agency (WADA) lists it under the S0 category of non-approved substances, banning it in competitive sports.
If you’re looking for peptides in Canada from a supplier that publishes COAs on every product, Boss Peptides provides third-party tested BPC-157 with full documentation.
Where to Buy BPC-157 in Canada
If you’ve decided to buy BPC-157 for research, sourcing is the most important decision you’ll make. The peptide market has no shortage of low-quality vendors selling untested or mislabeled products. Here’s what to look for:
A published Certificate of Analysis (COA) for every batch, showing HPLC purity of 98% or higher, mass spectrometry identity confirmation, sterility testing, and heavy metal screening. The COA should come from an independent third-party lab — not the company’s own internal testing.
Boss Peptides publishes COAs directly on each product page. Every batch of BPC-157 is tested by an independent Canadian lab before it reaches you. We ship across Canada with fast delivery — most orders arrive within 2–3 business days.
The Bottom Line
BPC-157 has over 30 years of preclinical research behind it, with consistent results across tendon, muscle, bone, gut, and vascular injury models. The mechanisms are increasingly well understood — VEGF-driven angiogenesis, growth hormone receptor upregulation, and anti-inflammatory effects being the primary drivers.
What it still lacks is robust human clinical data. The animal research is compelling, but peptides sometimes behave differently in humans than in rodents. Until properly designed clinical trials are completed, the evidence remains preclinical.
For researchers in Canada interested in this peptide, the key is to source from a supplier that prioritizes purity and transparency. Every vial of BPC-157 from Boss Peptides comes with third-party lab verification, so you know exactly what you’re working with.
Disclaimer: This article is for informational and educational purposes only. BPC-157 is sold for research purposes and is not approved for human therapeutic use by Health Canada or the FDA. Nothing in this article constitutes medical advice. Consult a qualified healthcare professional before beginning any peptide protocol.